Goal: 03 - Sağlık ve Kaliteli Yaşam
Loading...
Description
AMAÇ 3: SAĞLIKLI BİREYLER
Çocuk ölüm oranlarının azaltılması, anne sağlığının iyileştirilmesi, HIV/AIDS, sıtma ve diğer hastalıklar ile mücadelede büyük aşama kaydetmiş durumdayız. 1990 yılından bu yana, önlenebilir çocuk ölümlerinde dünya genelinde %50’yi aşan azalma olmuştur. Anne ölümleri de dünya genelinde %45 azalmıştır. 2000 ile 2013 arasında HIV/AIDS bulaşma oranı %30 azalmış, 6,2 milyonu aşkın insan sıtmadan kurtarılmıştır.
Bu ölümler; önleme ve tedavi, eğitim, aşı kampanyaları, cinsel ve üreme sağlığı hizmetleri vasıtasıyla önlenebilir. Sürdürülebilir Kalkınma Amaçları; AIDS, verem, sıtma ve diğer bulaşıcı hastalık salgınlarını 2030 yılına kadar ortadan kaldırmaya yönelik cesur bir taahhüttür. Amaç, herkesin genel sağlık hizmeti, güvenli ve erişilebilir ilaç ve aşıya kavuşmasını sağlamaktır. Aşı araştırma ve geliştirmelerinin desteklenmesi, bu sürecin vazgeçilmez bir parçasıdır.
2153 results
Publication Search Results
Now showing 1 - 10 of 2153
Publication Diyabetik ayak enfeksiyonu için kullanılan tigesikline bağlı ciddi hipoglisemi:(2018-10-07) Kazancıoğlu, Rümeyza; Gürsu, Meltem; KAZANCIOĞLU, RÜMEYZA; GÜRSU, MELTEMPublication Prognostic Factors for Operated Gallbladder Cancer.(2019-09-01T00:00:00Z) Oven, Ustaalioglu; Bilici, A; Seker, MESUT; Kefeli, U; Aydin, D; Celik, S; Demir, T; Erkol, B; ŞEKER, MESUTPublication Diyabetik hastalardaki sigara kullanımı ve kan şekeri regülasyonu ile ilişkisi(2011-05-15) ZORLU, MEHMET; KISKAÇ, MUHARREM; YOLBAŞ, SERVET; ÇAKIRCA, MUSTAFA; BÜYÜKAYDIN, BANU; ZORLU, MEHMET; KISKAÇ, MUHARREM; ÇAKIRCA, MUSTAFA; BÜYÜKAYDIN, BANUPublication Investigation of mean platelet volume in patients with type 2 diabetes mellitus and in subjects with impaired fasting glucose: a cost-effective tool in primary health care?(2014-01-01) Ozder, ACLAN; Eker, Hasan Huseyin; ÖZDER, ACLANThe aim of this study was to compare mean platelet volume (MPV) in patients with type 2 diabetes mellitus (T2DM), in subjects with impaired fasting glucose (IFG), and in non-diabetic controls. A total of 201 adults with T2DM and 201 subjects with IFG from the Family Medicine out-patient clinic as well as 201 healthy controls were included in the study. We measured blood fasting glucose, complete blood count and LDL-cholesterol and compared the results between the groups enrolled. In the patients with diabetes and subjects with IFG, MPV was significantly higher (10.66 ± 0.94 fL and 10.49 ± 0.96 fL, respectively ) as compared to the non-diabetic group (10.04 ± 1.01 fL) (p = 0.000). Among the diabetic subjects, a positive statistical Pearson correlation was seen between MPV and HbA1c levels (r = 0.357; p = 0.000) and fasting blood glucose (FBG) levels (r = 0.306; p = 0.000). The mean MPV in patients having HbA1C < 7.5% was 10.17 ± 0.83 fL and significantly lower than that of patients with HbA1c ≥ 7.5% (10.80 ± 0.92 fL) (p = 0.001). MPV could be used as a simple and cost-effective tool to monitor the progression and control of T2DM and thereby in preventing vascular events in primary health care.Publication Cancer chemoprevention research with selenium in the post-SELECT era: Promises and challenges.(2016-01-01) LÜ, J; ZHANG, J; JIANG, C; DENG, Y; Özten, NUR; BOSLAND, MC; ÖZTEN KANDAŞ, NURThe negative efficacy outcomes of double-blinded, randomized, placebo-controlled Phase III human clinical trials with selenomethionine (SeMet) and SeMet-rich selenized-yeast (Se-yeast) for prostate cancer prevention and Se-yeast for prevention of non-small cell lung cancer (NSCLC) in North America lead to rejection of SeMet/Se-yeast for cancer prevention in Se-adequate populations. We identify two major lessons from the outcomes of these trials: 1) The antioxidant hypothesis was tested in wrong subjects or patient populations. 2) The selection of Se agents was not supported by cell culture and preclinical animal efficacy data as is common in drug development. We propose that next-generation forms of Se (next-gen Se), such as methylselenol precursors, offer biologically appropriate approaches for cancer chemoprevention but these are faced with formidable challenges. Solid mechanism-based preclinical efficacy assessments and comprehensive safety studies with next-gen Se will be essential to re-vitalize the idea of cancer chemoprevention with Se in the post-SELECT era. We advocate smaller mechanism-driven Phase I/II trials with these next-gen Se to guide and justify future decisions for definitive Phase III chemoprevention efficacy trials.Publication Akciğerde Solid Kitle Görüntüsü Veren Tüberküloz Olgusu(2016-01-01T00:00:00Z) DİRİCAN, NİGAR; PINAR, MERVE; KAYA, ŞULE; BİRCAN, HACI AHMET; DÖNGEL, İSA; ÇAKIR, MÜNİRE; BİRCAN, HACI AHMETPublication Evaluation of therapeutics management patterns and glycemic control of pediatric type 1 diabetes mellitus patients in Turkey: A nationwide cross-sectional study(2016-09-01) Hatun, Sukru; DEMIRBILEK, Huseyin; DARCAN, ŞÜKRAN; Yuksel, Aysegul; Binay, Cigdem; Simsek, Damla Goksen; Kara, Cengiz; CETINKAYA, Ergun; UNUVAR, Tolga; UCAKTURK, Ahmet; Tutunculer, Filiz; Cesur, YAŞAR; Bundak, Ruveyde; Saglam, Halil; Simsek, Enver; Bereket, Abdullah; CESUR, YAŞARAims: To evaluate the management strategies, glycemic control and complications of pediatric type 1 diabetes mellitus (T1DM) patients in Turkey.Publication An Overview of COVID-19 Medicines in Current Guidelines(2020-12-01T00:00:00Z) GÖKÇE, MUSTAFA; GÜLER, ERAY METİN; GÖKÇE, MUSTAFA; GÜLER, ERAY METİNAn acute respiratory disease caused by a new coronavirus (Severe acute respirotary syndrome-coronavirus-2, previously known as 2019-nCoV), coronavirus disease 2019 (COVID-19), appeared in December 2019 and then has spread rapidly throughout the world starting from China, Japan and South Korea. As of January 30, 2020, the World Health Organization has officially declared the COVID-19 outbreak. Considering the clinical symptoms of COVID-19, it has many symptoms such as high fever, cough, and fatigue. It is reported that this disease is very severe and causes serious consequences such as cytokine storm and acute respiratory distress syndrome in the elderly and those with chronic diseases. Currently, scientists are trying to find a specific antiviral treatment strategy. Various medications such as hydroxychloroquine, lopinavir/ritonavir, ribavirin, remdesivir and favipiravir are currently being applied in clinical trials to test their efficacy and safety worldwide in COVID-19 treatment, and some promising results have been achieved so far. In this review, agents with potential efficacy against COVID-19 are presented in summary.Publication Is the Duration of Temozolomide Predictive for Sequential Bevacizumab Treatment Responses in the Glioblastoma Multiforme Cancer Setting?(2021-08-01T00:00:00Z) Besiroglu, Mehmet; Demir, Tarik; Shbair, Abdallah T M; Yasin, Ayse Irem; Topcu, Atakan; Turk, HACI MEHMET; TÜRK, HACI MEHMETPublication Tolerability of capecitabine in postoperative adjuvant chemotherapy in colon cancer: A single center study.(2014-05-20T00:00:00Z) NAMAL, Esat; Sut, PELİN; ASKAROGLU, Bulent; YILDIZ, Betul; PAMUKCU, Ozgul; ALTINOK SÜT, PELİN